trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Carcinoma D002277 18 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Brain Neoplasms D001932 15 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Melanoma D008545 69 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Asthma D001249 52 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Intellectual Disability D008607 13 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Prostatic Hyperplasia D011470 20 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Myeloproliferative Disorders D009196 5 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Carcinoma, Renal Cell D002292 12 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Leukemia, Promyelocytic, Acute D015473 3 associated lipids
Stroke D020521 32 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Nerve Degeneration D009410 53 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Tongue Neoplasms D014062 15 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Nasal Polyps D009298 26 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Mast-Cell Sarcoma D012515 9 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Neoplasms, Hormone-Dependent D009376 23 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Radiation Injuries D011832 14 associated lipids
Leishmaniasis D007896 19 associated lipids
Enteritis D004751 8 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Chondrosarcoma D002813 9 associated lipids
Osteomalacia D010018 5 associated lipids
Glioblastoma D005909 27 associated lipids
Keloid D007627 12 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Medulloblastoma D008527 22 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Cat Diseases D002371 12 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Polycystic Kidney, Autosomal Dominant D016891 6 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Retinoblastoma D012175 12 associated lipids
Genomic Instability D042822 7 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Mastocytoma D034801 3 associated lipids
Cell Transformation, Viral D002472 26 associated lipids
Nasopharyngeal Neoplasms D009303 4 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Adenocarcinoma, Follicular D018263 3 associated lipids
Hypereosinophilic Syndrome D017681 3 associated lipids
Retinal Neoplasms D019572 3 associated lipids
Progeria D011371 3 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Mai A et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. 2004 J. Med. Chem. pmid:14971890
Milhem M et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. 2004 Blood pmid:14976039
Agostinho M et al. Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis. 2004 Mol. Biol. Cell pmid:14978217
Sakata R et al. Trichostatin A activates the osteopontin gene promoter through AP1 site. 2004 Biochem. Biophys. Res. Commun. pmid:14985105
Lu XC et al. [Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]. 2004 Zhongguo Shi Yan Xue Ye Xue Za Zhi pmid:14989767
Nojima H et al. Increase in DNA methylation downregulates conceptus interferon-tau gene expression. 2004 Mol. Reprod. Dev. pmid:14991730
Chua YL et al. Microarray analysis of chromatin-immunoprecipitated DNA identifies specific regions of tobacco genes associated with acetylated histones. 2004 Plant J. pmid:14996214
Khan AN et al. An epigenetically altered tumor cell vaccine. 2004 Cancer Immunol. Immunother. pmid:14997346
Ragno R et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. 2004 J. Med. Chem. pmid:14998325
Hwang CK et al. Transcriptional regulation of mouse mu opioid receptor gene by PU.1. 2004 J. Biol. Chem. pmid:14998994
Astrand C et al. Trichostatin A reduces hormone-induced transcription of the MMTV promoter and has pleiotropic effects on its chromatin structure. 2004 Eur. J. Biochem. pmid:15009194
Gray SG et al. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. 2004 Int. J. Oncol. pmid:15010814
Huang H et al. Expression of P53, P21 in human lung adenocarcinoma A549 cell strains under hypoxia conditions and the effect of TSA on their expression. 2003 J. Huazhong Univ. Sci. Technol. Med. Sci. pmid:15015635
Aapola U et al. Epigenetic modifications affect Dnmt3L expression. 2004 Biochem. J. pmid:15015937
Knobbe CB et al. Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. 2004 J. Natl. Cancer Inst. pmid:15026474
Chung YL et al. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. 2004 Mol. Cancer Ther. pmid:15026552
Burton GR et al. Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. 2004 Gene pmid:15033539
David GL et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. 2004 Cancer Biol. Ther. pmid:15034303
Liu X et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. 2004 Biochem. Pharmacol. pmid:15041467
Steiner E et al. SP-transcription factors are involved in basal MVP promoter activity and its stimulation by HDAC inhibitors. 2004 Biochem. Biophys. Res. Commun. pmid:15047174
Kypreou KP et al. Age-dependent response of lymphocytes in the induction of the linker histone variant, H1 degrees and histone H4 acetylation after treatment with the histone deacetylase inhibitor, trichostatin A. 2004 Exp. Gerontol. pmid:15050280
Chen YX et al. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines]. 2004 Zhonghua Yi Xue Za Zhi pmid:15059516
Hildmann C et al. A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases. 2004 J. Bacteriol. pmid:15060035
Vorontsova M et al. Effect of 5-azacytidine and trichostatin A on somatic centromere association in wheat. 2004 Genome pmid:15060593
Tong X et al. Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. 2004 Biochem. Biophys. Res. Commun. pmid:15063780
Ganslmayer M et al. A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. 2004 Oncol. Rep. pmid:15069530
Margueron R et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. 2004 J. Mol. Endocrinol. pmid:15072561
Romanski A et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. 2004 Haematologica pmid:15075075
Ahmed S et al. A novel protein with similarities to Rb binding protein 2 compensates for loss of Chk1 function and affects histone modification in fission yeast. 2004 Mol. Cell. Biol. pmid:15082762
Amor DJ et al. Human centromere repositioning "in progress". 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:15084747
Milutinovic S et al. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. 2004 J. Biol. Chem. pmid:15087453
Chang HC et al. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. 2004 Cell. Signal. pmid:15093608
Munro J et al. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. 2004 Exp. Cell Res. pmid:15093749
Tani M et al. Correlation between histone acetylation and expression of the MYO18B gene in human lung cancer cells. 2004 Genes Chromosomes Cancer pmid:15101048
Jansen MS et al. Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:15103026
Lasa A et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. 2004 Leukemia pmid:15103390
Yokota T et al. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. 2004 Oncogene pmid:15107822
McGarry LC et al. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. 2004 Oncogene pmid:15107823
Nishino N et al. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. 2004 Bioorg. Med. Chem. Lett. pmid:15109626
Marson CM et al. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. 2004 Bioorg. Med. Chem. Lett. pmid:15109636
Arapshian A et al. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. 2004 Mol. Cancer pmid:15113415
Mizukami T et al. Effects of trichostatin a, a histone deacetylase inhibitor, on mouse gonadal development in vitro. 2004 J. Reprod. Dev. pmid:15118250
Klampfer L et al. Requirement of histone deacetylase activity for signaling by STAT1. 2004 J. Biol. Chem. pmid:15123634
Fu M et al. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. 2004 J. Biol. Chem. pmid:15123687
Phan D et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 2004 Cancer Res. pmid:15126343
Iezzi S et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. 2004 Dev. Cell pmid:15130492
Bort R et al. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. 2004 Arch. Biochem. Biophys. pmid:15130783
Ishii S et al. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone. 2004 Mol. Endocrinol. pmid:15131262
Winn RA and Heasley LE Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. 2004 Chest pmid:15136458
Jin YH et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. 2004 J. Biol. Chem. pmid:15138260